Free Trial

Laboratory Co. of America (LH) Stock Price, News & Analysis

+3.28 (+1.67%)
(As of 05/24/2024 07:00 PM ET)
Today's Range
50-Day Range
52-Week Range
724,500 shs
Average Volume
751,041 shs
Market Capitalization
$16.83 billion
P/E Ratio
Dividend Yield
Price Target

Laboratory Co. of America MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.79 Rating Score
21.8% Upside
$243.14 Price Target
Short Interest
2.47% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
1.57mentions of Laboratory Co. of America in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$5.11 M Sold Last Quarter
Proj. Earnings Growth
From $14.87 to $15.96 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.87 out of 5 stars

Medical Sector

35th out of 921 stocks

Medical Laboratories Industry

2nd out of 19 stocks

LH stock logo

About Laboratory Co. of America Stock (NYSE:LH)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

LH Stock Price History

LH Stock News Headlines

Lancorp Launches First Trimester Preeclampsia Screening Test
Labcorp Announces 2024 First Quarter Results
See More Headlines
Receive LH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Laboratory Co. of America and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/13 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 6/12 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medical laboratories
Health Care Services
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
14 Analysts


Net Income
$418 million
Pretax Margin


Sales & Book Value

Annual Sales
$12.16 billion
Cash Flow
$20.33 per share
Book Value
$94.42 per share


Free Float
Market Cap
$16.83 billion

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

LH Stock Analysis - Frequently Asked Questions

Should I buy or sell Laboratory Co. of America stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last twelve months. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LH shares.
View LH analyst ratings
or view top-rated stocks.

What is Laboratory Co. of America's stock price target for 2024?

14 Wall Street analysts have issued 12-month target prices for Laboratory Co. of America's stock. Their LH share price targets range from $210.00 to $270.00. On average, they predict the company's share price to reach $243.14 in the next year. This suggests a possible upside of 21.8% from the stock's current price.
View analysts price targets for LH
or view top-rated stocks among Wall Street analysts.

How have LH shares performed in 2024?

Laboratory Co. of America's stock was trading at $227.29 at the beginning of the year. Since then, LH shares have decreased by 12.2% and is now trading at $199.65.
View the best growth stocks for 2024 here

Are investors shorting Laboratory Co. of America?

Laboratory Co. of America saw a decrease in short interest in April. As of April 30th, there was short interest totaling 2,070,000 shares, a decrease of 8.4% from the April 15th total of 2,260,000 shares. Based on an average trading volume of 795,100 shares, the short-interest ratio is currently 2.6 days. Approximately 2.5% of the shares of the company are short sold.
View Laboratory Co. of America's Short Interest

When is Laboratory Co. of America's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our LH earnings forecast

How were Laboratory Co. of America's earnings last quarter?

Laboratory Co. of America Holdings (NYSE:LH) released its earnings results on Thursday, April, 25th. The medical research company reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.48 by $0.20. The medical research company had revenue of $3.18 billion for the quarter, compared to analyst estimates of $3.12 billion. Laboratory Co. of America had a net margin of 3.52% and a trailing twelve-month return on equity of 14.68%. The business's quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.82 earnings per share.
Read the conference call transcript

How often does Laboratory Co. of America pay dividends? What is the dividend yield for Laboratory Co. of America?

Laboratory Co. of America announced a quarterly dividend on Thursday, April 11th. Investors of record on Tuesday, May 28th will be paid a dividend of $0.72 per share on Wednesday, June 12th. This represents a $2.88 annualized dividend and a yield of 1.44%. The ex-dividend date of this dividend is Friday, May 24th.
Read our dividend analysis for LH

Is Laboratory Co. of America a good dividend stock?

Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.44%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 57.95%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 18.05% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LH.

What guidance has Laboratory Co. of America issued on next quarter's earnings?

Laboratory Co. of America issued an update on its FY24 earnings guidance on Thursday, April, 25th. The company provided earnings per share guidance of $14.45-15.35 for the period, compared to the consensus EPS estimate of $14.84.

What is Adam Schechter's approval rating as Laboratory Co. of America's CEO?

143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Adam Schechter has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Laboratory Co. of America own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), Abbott Laboratories (abt), AbbVie (ABBV), Alibaba Group (BABA) and Amgen (AMGN).

Who are Laboratory Co. of America's major shareholders?

Laboratory Co. of America's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.43%), Lazard Asset Management LLC (2.02%), Allspring Global Investments Holdings LLC (1.92%), Lord Abbett & CO. LLC (0.88%), Bank of New York Mellon Corp (0.81%) and Nordea Investment Management AB (0.77%). Insiders that own company stock include Amy B Summy, Brian J Caveney, Der Vaart Sandra D Van, Dwight Gary Gilliland, Glenn A Eisenberg, Jonathan P Divincenzo, Kerrii B Anderson, Mark S Schroeder, Paul R Kirchgraber, Peter J Wilkinson, Peter M Neupert and R Sanders Williams.
View institutional ownership trends

How do I buy shares of Laboratory Co. of America?

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Laboratory Co. of America have any subsidiaries?
The following companies are subsidiares of Laboratory Co. of America: 1957285 Ontario Inc. dba Quality Underwriting Services, 2089729 Ontario Inc., 2248848 Ontario Inc., 3065619 Nova Scotia Company, 3257959 Nova Scotia Company, 8165335 Canada Inc., 8348596 Canada Inc., 896988 Ontario Limited, 9279-3280 Quebec Inc., Accupath Diagnostic Laboratories Inc., Assets of Pathology Inc, Beacon LBS IPA Inc., Beacon Laboratory Benefit Solutions Inc., CannAmm GP Inc., CannAmm Limited Partnership, Center for Disease Detection International, Center for Disease Detection LLC, Centrex Clinical Laboratories Inc., Chiltern, Clearstone Central Laboratories (U.S.) Inc., Clearstone Holdings (International) Ltd., Clinical Outreach Laboratory Services, Clipper Holdings Inc., Colorado Coagulation Consultants Inc., Colorado Laboratory Services LLC, Correlagen Diagnostics Inc., Covance Inc., Curalab Inc., Cytometry Associates Inc., Czura Thornton (Hong Kong) Limited, DCL Acquisition Inc., DCL Medical Laboratories LLC, DCL Sub LLC, DIANON Systems Inc., DL Holdings Limited Partnership, Decision Diagnostics L.L.C. (aka DaVinici/Medicorp LLC), Diagnostic Services Inc., DynaLifeDX, Dynacare - Gamma Laboratory Partnership, Dynacare Company, Dynacare G.P. Inc., Dynacare Holdco LLC, Dynacare Laboratories Inc., Dynacare Laboratories Limited Partnership, Dynacare Northwest Inc., Dynacare Realty Inc., DynalifeDX Infrastructure Inc., Envigo's nonclinical contract research services business, Esoterix Genetic Counseling LLC, Esoterix Genetic Laboratories LLC, Esoterix Inc., Execmed Health Services Inc., FirstSource Laboratory Solutions Inc., GDML Medical Laboratories Inc, Gamma Dynacare Central Medical Laboratories GP Inc., Gamma Dynacare Central Medical Laboratory Limited Partnership, HHLA Lab-In-An-Envelope LLC, Health Testing Centers Inc., Health Trans Services Inc., Home Healthcare Laboratory of America LLC, IDX Pathology Inc., Impact Genetics Corporation, Impact Genetics Inc., Kaleida LabCorp LLC, Lab Delivery Service of New York City Inc., LabCorp BVBA, LabCorp Belgium Holdings Inc., LabCorp Central Laboratories (Canada) Inc., LabCorp Central Laboratories (China) Inc., LabCorp Colorado Inc., LabCorp Development Company, LabCorp Employer Services Inc., LabCorp Health System Diagnostics LLC, LabCorp Indiana Inc., LabCorp Japan G.K., LabCorp Limited, LabCorp Michigan Inc., LabCorp Nebraska Inc., LabCorp Neon Ltd., LabCorp Neon Switzerland S.à.r.l., LabCorp Specialty Testing Billing Service Inc., LabCorp Specialty Testing Group Inc., LabCorp Staffing Solutions Inc., LabCorp Tennessee LLC, LabCorp UK Holdings Ltd., LabWest Inc., Laboratoire Bio-Medic Inc., Laboratory Corporation of America, Lifecodes Corporation, LipoScience Inc., Litholink Corporation, MEDTOX Scientific Inc., MNG Laboratories, MedAxio Insurance Medical Services GP Inc., MedAxio Insurance Medical Services LP, Medical Neurogenitics LLC, Medtox Diagnostics Inc., Medtox Laboratories Inc., Monogram Biosciences Inc., Monogram Biosciences UK Limited, Myriad Autoimmune’s Vectra Testing Business, NWT Inc., National Genetics Institute, New Brighton Business Center LLC, New Imaging Diagnostics LLC, New Molecular Diagnostics Ventures LLC, Orchid Cellmark ULC, Ovia Health, PA Labs Inc., Paclab LLC, Path Lab Incorporated, Pathology Associates Medical Lab LLC, Pee Dee Pathology Associates Inc., Personal Genome Diagnostics Inc., Persys Technology Inc., Pixel by LabCorp, Princeton Diagnostic Laboratories of America Inc., Protedyne Corporation, SW/DL LLC, Saint Josephs-PAML LLC, Sequenom Biosciences (India) Pvt. Ltd., Sequenom Inc, Sequenom Inc., Tandem Labs Inc., Toxikon Corporation, Tri-Cities Laboratory LLC, Viro-Med Laboratories Inc., Visiun, and Yakima Medical Arts Inc..
Read More
This page (NYSE:LH) was last updated on 5/27/2024 by Staff

From Our Partners